[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360010-105":59,"doc-detail-360010-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","anlotinib-plus-envafolimab-as-neoadjuvant-therapy-in-a-patient-with-chemotherapy-refractory-advanced-endometrial-cancer-a-case-report","Anlotinib plus envafolimab as neoadjuvant therapy in a patient with chemotherapy-refractory advanced endometrial cancer - A case report","","A case report describes a 51-year-old woman with synchronous double primary malignancies: advanced endometrial cancer and early-stage lung cancer. After one year post-chemotherapy withdrawal due to toxicity, she developed severe urinary retention and poor performance status from pelvic tumor progression. Deemed ineligible for standard chemoradiotherapy, she received anlotinib plus envafolimab, achieving rapid symptom relief and marked tumor regression, enabling conversion to surgical candidacy. She underwent curative laparoscopic surgery with R0 resection and stereotactic radiation for the lung lesion; she remains disease-free at follow-up.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/anlotinib-plus-envafolimab-as-neoadjuvant-therapy-in-a-patient-with-chemotherapy-refractory-advanced-endometrial-cancer-a-case-report/360010/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/anlotinib-plus-envafolimab-as-neoadjuvant-therapy-in-a-patient-with-chemotherapy-refractory-advanced-endometrial-cancer-a-case-report/360010.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why was the patient not eligible for standard chemoradiotherapy?","Question",{"text":112,"@type":113},"She had severe urinary retention and poor performance status driven by pelvic tumor progression after stopping chemotherapy due to toxicity, making standard chemoradiotherapy unsuitable.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What treatment regimen was used as neoadjuvant therapy?",{"text":117,"@type":113},"She received anlotinib combined with envafolimab, an antiangiogenic TKI plus a subcutaneous PD-L1 antibody, aimed at rapid tumor control and downstaging.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key clinical outcomes after this conversion therapy?",{"text":121,"@type":113},"Symptoms resolved quickly and tumors regressed substantially, allowing conversion to surgery with R0 resection; the lung lesion was treated with stereotactic body radiation, and she remains disease-free on follow-up.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360010,1790198655,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","CASE REPORT  \nAnlotinib plus envafolimab as neoadjuvant therapy in a patient with chemotherapy-refractory advanced endometrial cancer: A case report  \nJinpeng Xu, Dunmin Zhuang, Lijie Wang, Lina Dong, Yang Sun, and Wenjing Xiao Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China  \nABSTRACT  \nWe report a case of a 51-y-old female presenting with synchronous double primary malignancies: advanced endometrial cancer and early-stage lung cancer. One year a post-chemotherapy withdrawal due to toxicity, she developed severe urinary retention and poor performance status caused by pelvic tumor progression. Considered ineligible for standard chemoradiotherapy, she received anlotinib (a novel multi-target TKI) combined with envafolimab (a subcutaneous PD-L1 antibody). This regimen resulted in rapid symptom resolution and significant tumor regression, successfully converting the patient to surgical candidacy. She subsequently underwent laparoscopic hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy, achieving an R0 resection. The lung lesion was treated with stereotactic body radiation therapy. She remains diseasefree at follow-up. The combination of anlotinib and envafolimab shows promise as an effective conversion therapy for endometrial cancer, particularly in patients with advanced stage, poor performance status, or intolerance to intensive treatments.  \nPLAIN LANGUAGE SUMMARY  \nWe treated a patient who had two types of cancer at the same time: advanced cancer of the uterine lining (endometrial cancer) and early-stage lung cancer. The patient was very weak and could not tolerate standard chemotherapy or radiation because of severe side effects and complications from the pelvic tumor. We tried a combination of two drugs, anlotinib and envafolimab, to shrink the tumor and improve her condition. This treatment worked quickly, relieving her symptoms and shrinking the cancer enough to make surgery possible. The patient then underwent successful surgery to remove the gynecological tumor and received focused radiation for the lung tumor. She is currently cancer-free. This case suggests that this drug combination may help patients with advanced endometrial cancer who cannot handle harsh standard treatments, offering them a chance for curative surgery.  \nARTICLE HISTORY  \nReceived 8 October 2025 Revised 3 March 2026 Accepted 23 March 2026  \nKEYWORDS  \nEndometrial cancer; anlotinib; envafolimab; neoadjuvant therapy; immune checkpoint inhibitor; antiangiogenic therapy; case report  \nIntroduction  \nEndometrial cancer (EC) is the second most common gynecological malignancy globally, with a rising incidence and significant mortality, accounting for 417,367 new cases and 97,370 deaths worldwide in 2020.1,2 Although the majority of patients (over 70%) are diagnosed with early-stage (Stage I) disease and have an excellent prognosis with a five-year survival rate exceeding 90%, outcomes for advanced disease are starkly different.3 For patients with Stage III and IV EC, five-year survival rates decline dramatically to 56% and 17%, respectively.2,3 Consequently, while patients with advanced EC constitute only 10–15% of all cases, they account for over half of all EC-related deaths, with a median survival of just 2–8 months for those withinoperable disease.4,5  \nThe cornerstone of EC management is surgical resection, often supplemented by adjuvant radiotherapy, chemotherapy, or endocrine therapy. Contemporary guidelines recommend individualized treatment plans based on factors such as patient age, performance status, disease extent, and molecular classification.6 For patients presenting with locally advanced disease deemed unresectable, neoadjuvant chemotherapy may be employed to achieve cytoreduction and downstaging, thereby enabling definitive surgery.7 However, conventional cytotoxic regimens are often associated with significant toxicity and severe adverse events,  \nCONTACT Wenjing ","cbCaiessuZ4cj7JG","https://ap.wps.com/l/cbCaiessuZ4cj7JG","pdf",3943277,"English","# Introduction\n# Article history\n# Keywords\n# Case description\n## Treatment rationale\n## Treatment regimen and outcomes","[{\"question\":\"Why was the patient not eligible for standard chemoradiotherapy?\",\"answer\":\"She had severe urinary retention and poor performance status driven by pelvic tumor progression after stopping chemotherapy due to toxicity, making standard chemoradiotherapy unsuitable.\"},{\"question\":\"What treatment regimen was used as neoadjuvant therapy?\",\"answer\":\"She received anlotinib combined with envafolimab, an antiangiogenic TKI plus a subcutaneous PD-L1 antibody, aimed at rapid tumor control and downstaging.\"},{\"question\":\"What were the key clinical outcomes after this conversion therapy?\",\"answer\":\"Symptoms resolved quickly and tumors regressed substantially, allowing conversion to surgery with R0 resection; the lung lesion was treated with stereotactic body radiation, and she remains disease-free on follow-up.\"}]","Anlotinib plus envafolimab as neoadjuvant therapy in a patient with chemotherapy-refractory advanced endometrial cancer - A case report | PDF",1790138499,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97dc591eeceea4c8509afac44a93ecf1.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c719208b42746200d186be0907a9ec80.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df7ec10066683bffd11c915db766617f.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c537af91315fb14fa4c81a41ea4b98f.webp",980,1306]